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To be or not 
to be exclusive: 
the sutezolid story
Response from Johns Hopkins 
University
Johns Hopkins University is deeply 
committed to providing access to 
essential medicines, and has been 
working for years to advance the goal 
of ensuring that promising therapies 
for tuberculosis reach the market in an 
expeditious and accessible way.  
As with other promising drugs in the 
early stages of development, sutezolid 
is not yet ready for patients, and 
will require costly development and 
approval steps before it can help to 
address tuberculosis. 
At this stage, there are scant data on 
sutezolid’s safety or eﬃ  cacy in patients 
with tuberculosis. A series of clinical 
trials, which typically cost more than 
US$50 million, will be required to 
understand these issues and inform 
potential benefits versus potential 
risks to patients. Sutezolid’s early 
stage of clinical development sets it 
apart from the in-market or late-stage 
clinical development HIV medicines 
targeted by the Medicines Patent 
Pool.1
In this case, the story is further 
complicated by the fact that Johns 
Hopkins University does not own 
patent rights for the sutezolid 
compound; thus, our intellectual 
property is not necessary for the 
clinical development and com-
mercialisation of sutezolid itself. Johns 
Hopkins is part of a jointly assigned 
patent application with Pfizer Inc 
entitled “Combination therapy for 
tuberculosis” (WO2010026526A1), 
and is limited to the use of sutezolid in 
combination with other compounds 
to treat tuberculosis.
The development of sutezolid 
requires a strong outside partner 
who can take on the costs and risks 
of the next steps: but such a partner 
is unlikely to be found without 
an appropriate set of assurances 
around their ability to recover their 
investment. Our challenge is to 
ensure that we provide the incentives 
to invest in the development of this 
compound, while also promoting our 
interest in the widespread distribution 
of medicines at an aﬀ ordable price.
As researchers and clinicians 
devoted to human health, Johns 
Hopkins University aims to ensure the 
best use of its intellectual property. 
Indeed, we seek to partner with those 
organisations who are most willing 
to pursue development, obtain 
regulatory approval, and bring this 
promising combination technology 
to patients. Furthermore, we aim to 
respond to the great unmet global 
need around tuberculosis and the 
dearth of companies investing in this 
area.
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